Advertisement.

RPTX Projected Dividend Yield

Repare Therapeutics Inc ( NASDAQ : RPTX )

Repare Therapeutics Inc. is a clinical-stage precision oncology company that uses a synthetic lethality approach to develop novel cancer therapeutics. Its SNIPRx platform, enabled by CRISPR, helps discover targeted therapies focused on genomic instability and DNA damage repair. The pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 trials; camonsertib (RP-3500), an ATR inhibitor in Phase 1/2 trials; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta ATPase inhibitor; and other undisclosed preclinical programs. RP-3500 is an oral ATR inhibitor for treating solid tumors with DNA damage repair-related genomic alterations.

21 YEAR PERFORMANCE RESULTS

RPTX Dividend History Detail
RPTX Dividend News
RPTX Competitors News

# of Shares: 0

Closing Price: 1.00

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000